Analyst Blog
....We note that Amgen stumbled with its oncology pipeline earlier this
month as well when its experimental ovarian cancer treatment,
trebananib, failed to meet the secondary endpoint of overall survival in
a late-stage study. Although trebananib had achieved the primary endpoint of the study,
overall survival is an important criterion for gaining FDA approval.
Moreover, the rate of discontinuation due to adverse events was much
higher in the trebananib arm compared to the control arm (20% versus
7%).....
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.